Abstract
We prospectively investigated the correlation between DISC-assay results and clinical response and also survival in patients with AML using a new method of evaluation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Delmer A, Marie JP, Thevenin D, Cadiou M, Viguie F and Zittoun R. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin Onc 1989, 7, 738–746.
Weisenthal LM, Dill PL, Kurnick NB and Lippman ME. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 1983, 43, 258–264.
Weisenthal LM, Marsden JA, Dill PL and Macaluso CK. A novel dye exclusion test for testing in-vitro chemosensitivity of human tumors. Cancer Res 1983, 43, 749–757
Kirkpatrick DL, Duke M, Goh TS. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leukemia Res 1990, 14, 459–466.
Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier A, Westra G and Veerman AJP. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996, 93, 903–910.
Pieters R, Huismans DR, Loonen AH, Hählen K, Van der Does-van den Berg A, van Wering ER and Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991, 338, 399–403.
Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989, 60, 206–210.
Bird MC, Godwin VAJ, Antrobus JH, Bosanquet AG. Comparison of in-vitro drug sensitivity by the differential staining cytotoxicity (DISC) assay and colony-forming assays. Br J Cancer 1987, 55, 429–431.
Bird MC, Bosanquet AG, Forskitt S, Gilby ED. Semi-micro adaption of a 4-day differential staining cytotoxicity (DISC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res 1986, 10, 445–449.
Bosanquet AG. The DISC assay—10 years and 2000 tests further on. In: Kaspers GJL, Pieters R, Twenty-man PR, Weisenthal LM & Veerman AJP, Eds. Drug Resistance in Leukemia and Lymphoma. The Clinical Value of Laboratory Studies. Harwood, London. 1993, 373–384.
Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug sensitivity assay. Lancet 1991, 337, 711–714.
Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER and Veerman AJP. In-vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991, 64, 469–474.
Bosanquet AG. In-vitro drug sensitivity testing for the individual patient: an ideal adjunct to current methods of treatment choice. Clin Oncol 1993, 5, 195–197.
Bosanquet AG. Short-term in-vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations ot test result with both patient response and survival. Forum Trends Exp. Clin. Med. 1994, 4, 179–189.
Lathan B, von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. In: Büchner T, Schellong G, Hiddemann W, Ritter J. eds. Haematology and Blood Transfusion. Vol. 33. Acute Leukemias II. Springer Verlag, Berlin, Heidelberg, 1990, 295–298.
Staib P., Lathan B., Michel K., Janz E., Schinköthe T. and Diehl V. Predictive value of pretherapeutic in-vitro chemosensitivity testing in adult AML. Haematology and Blood Transfusion 1998, 39, 509–519.
Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W et al. Intensive consolidation versus prolonged maintenance following intensive induction and conventional consolidation in primary AML: a study by AMLCG. Blood 1996, 88, No 10, Suppl. 1, 214a.
Wickramanayke PD, Steinmetz HT, Katay I, Glasmacher A, Staib P and Diehl V. Phase II trial of idarubicine, fludarabine, Ara-C and filgrastim (G-CSF) (Ida-FLAG) for the treatment of poor prognosis acut myeloid leukemia (AML). Blood 1995, 86, No 10, suppl. 1, 755a.
Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vitro intracellular drug concentrations. Eur J Haematol 1989, 43, 374–384.
Veerman AJP and Pieters R. Drug sensitivity assays in leukemia and lymphoma. Br J Haematol 1990, 74, 381–384.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Staib, P. et al. (1999). Prognosis in Adult AML is Precisely Predicted by the Disc-Assay Using the Chemosensitivity-Index CI . In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_47
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive